HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASA Clears RB Of Misleading UK Consumers In Two Nurofen Ads

Executive Summary

The UK's Advertising Standards Authority has cleared Reckitt Benckiser of misleading British consumers with two advertisements for its Nurofen brand of analgesics.

You may also be interested in...



Comparison Claims Must Be Verifiable, UK Ad Regulator Warns Reckitt

Failure to give consumers opportunity to verify claims made in an ad for its Lemsip cold and flu brand has landed Reckitt Benckiser in hot water with the UK Advertising Standards Authority. 

Ouch! Two UK Analgesic Ad Complaints: Reckitt Rapped, Perrigo Pardoned

Two UK advertising complaint verdicts delivered by the MHRA, Reckitt Benckiser's Nurofen Express (upheld) and Perrigo's Solpadeine Max (not upheld).

Reckitt Benckiser Exploring AI With Help Of Israeli Start-Ups

RB is looking to work with Israeli start-ups that can utilize emerging digital technologies to provide 'real world' consumer healthcare solutions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148444

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel